BioCentury | Jan 20, 2016
Top Story

Acorda adds to PD portfolio with Biotie takeout

...to treat other types of dementia, including Alzheimer's disease (AD). Acorda also will gain Biotie's BTT-1023...
BioCentury | Apr 13, 2015
Clinical News

BTT-1023: Phase IIa started

...the open-label, U.K. Phase IIa BUTEO trial to evaluate 7 doses of 8 mg/kg IV BTT1023...
...16 mg/kg in some patients. Biotie Therapies Corp . (HSE:BTH1V), Turku, Finland Product: BTT-1023 , BTT1023...
BioCentury | Oct 7, 2013
Company News

Biotie neurology, hepatic news

...FDA (see BioCentury, June 10). Biotie also decided to conduct a Phase II trial with BTT-1023...
...liver. The company said it is in advanced discussions for non-dilutive co-funding for the trial. BTT-1023...
...Biotie mutually terminated an April 2003 deal granting Seikagaku exclusive rights to develop and commercialize BTT-1023...
BioCentury | Apr 30, 2012
Company News

Biotie, Seikagaku deal

...exclusive rights to develop and commercialize BTT-1023 in Japan, Taiwan, Singapore, New Zealand and Australia. BTT-1023...
...start Phase II testing in 2H12 in yet to be determined inflammatory or fibrosis indication. BTT-1023...
BioCentury | Jan 17, 2011
Company News

Biotie, Synosia deal

...inhibitor, which is in Phase I testing to treat chronic obstructive pulmonary disease (COPD); and BTT-1023...
BioCentury | Jan 3, 2011
Finance

Trickle-down effect

...phosphodiesterase-4 (PDE-4) inhibitor in Phase I testing to treat chronic obstructive pulmonary disorder (COPD), and BTT-1023...
BioCentury | Jan 3, 2011
Company News

Biotie autoimmune, pulmonary news

...its early-stage discovery efforts in order to focus on the clinical development of ronomilast and BTT-1023...
...inhibitor that is in Phase I testing to treat chronic obstructive pulmonary disorder (COPD) and BTT-1023...
BioCentury | Nov 1, 2010
Finance

Regulatory Milestones

...it discontinues early-stage discovery. The company will focus on the clinical development of ronomilast and BTT-1023...
...Ronomilast is in Phase I testing to treat chronic obstructive pulmonary disorder (COPD), and BTT-1023...
BioCentury | Nov 1, 2010
Company News

Biotie, Roche deal

...a sale or licensing deal. In April, Roche did not exercise its option to license BTT-1023...
BioCentury | Nov 1, 2010
Company News

Biotie autoimmune, pulmonary news

...its early-stage discovery efforts in order to focus on the clinical development of ronomilast and BTT-1023...
...inhibitor that is in Phase I testing to treat chronic obstructive pulmonary disorder (COPD) and BTT-1023...
Items per page:
1 - 10 of 19